Drug Science publish regular articles that analyse developments in drug science and policy to highlight areas of improvement based on evidence

Get Project Twenty21 Updates via Email We recently announced a change to the pricing model of Project Twenty21. We understand that the news was unwelcome for some patients, especially for those who are prescribed higher dosages or on significantly lower incomes. We take people’s concerns seriously, and recognise that patients would…

Update What you have helped us achieve so far Our medical cannabis registry, Project Twenty21, was originally designed to run until the end of 2021 (hence the name). As you will know from your own life during the pandemic, the last two years have been full of challenges and obstacles. Project…

The available data for drug-related trends in the UK, and around the world, is extremely lacking. Crime surveys and national statistics have a narrow scope due to the limited data which they collect. Enter the Global Drug Survey (GDS), which collects data directly from people who have experience with drugs and…

Get Project Twenty21 Updates via Email To mark the end of the year that is our namesake, we're proud to announce that we've reached 2000 patients contributing their data to Project Twenty21. In a recent article for Cannabis Health, our Head of Development, David Horn, reflects on the last two years and…

The British Paediatric Neurology Association (BPNA) recently produced new guidance on the prescription of cannabis medicines for children with epilepsy. However, the Medical Cannabis Clinicians Society (UKMCCS) and Drug Science fundamentally disagree with this guidance. Expert clinicians from both organisations have produced a critique to provide commentary, evidence and further crucial information…